TerminatedNCT01940887
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy
PHASE3 · 645 planned enrolment
- Countries listed
- 22
- Registry update
- October 31, 2024
